Maravai LifeSciences Holdings Inc
MRVI3.270USD
-0.030-0.91%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
473.23MMarket Cap
LossP/E TTM
More Details of Maravai LifeSciences Holdings Inc Company
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Maravai LifeSciences Holdings Inc Info
Ticker SymbolMRVI
Company nameMaravai LifeSciences Holdings Inc
IPO dateNov 20, 2020
CEOBrust (Bernd)
Number of employees570
Security typeOrdinary Share
Fiscal year-endNov 20
Address10770 Wateridge Circle Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585460004
Websitehttps://www.maravai.com/
Ticker SymbolMRVI
IPO dateNov 20, 2020
CEOBrust (Bernd)
Company Executives of Maravai LifeSciences Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
North America
30.64M
64.64%
Europe, the Middle East and Africa
8.39M
17.71%
Asia Pacific
8.16M
17.21%
Latin and Central America
327.00K
0.69%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
Other
60.24%
Shareholders
Shareholders
Proportion
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
Other
60.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.58%
Hedge Fund
25.00%
Investment Advisor/Hedge Fund
17.45%
Private Equity
13.89%
Individual Investor
6.63%
Corporation
6.17%
Research Firm
4.39%
Pension Fund
0.20%
Bank and Trust
0.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GTCR Golder Rauner, LLC
20.15M
13.93%
--
--
Jun 30, 2025
12 West Capital Management, L.P.
12.52M
8.65%
--
--
Jun 30, 2025
Hudson View Capital LLC
6.87M
4.75%
+6.87M
--
May 21, 2025
Braidwell LP
8.35M
5.77%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
5.81%
+52.73K
+0.63%
Jun 30, 2025
The Vanguard Group, Inc.
9.38M
6.48%
-2.26M
-19.38%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
2.64M
1.83%
+2.64M
--
Jun 30, 2025
Mackenzie Investments
6.07M
4.2%
-44.32K
-0.72%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
2.89%
+75.50K
+1.84%
Jun 30, 2025
Mirabella Financial Services LLP
3.75M
2.59%
+10.05K
+0.27%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Global X Genomics & Biotechnology ETF
Proportion0.41%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Maravai LifeSciences Holdings Inc?
The top five shareholders of Maravai LifeSciences Holdings Inc are:
GTCR Golder Rauner, LLC holds 20.15M shares, accounting for 13.93% of the total shares.
12 West Capital Management, L.P. holds 12.52M shares, accounting for 8.65% of the total shares.
Hudson View Capital LLC holds 6.87M shares, accounting for 4.75% of the total shares.
Braidwell LP holds 8.35M shares, accounting for 5.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.41M shares, accounting for 5.81% of the total shares.
GTCR Golder Rauner, LLC holds 20.15M shares, accounting for 13.93% of the total shares.
12 West Capital Management, L.P. holds 12.52M shares, accounting for 8.65% of the total shares.
Hudson View Capital LLC holds 6.87M shares, accounting for 4.75% of the total shares.
Braidwell LP holds 8.35M shares, accounting for 5.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.41M shares, accounting for 5.81% of the total shares.
What are the top three shareholder types of Maravai LifeSciences Holdings Inc?
The top three shareholder types of Maravai LifeSciences Holdings Inc are:
GTCR Golder Rauner, LLC
12 West Capital Management, L.P.
Hudson View Capital LLC
GTCR Golder Rauner, LLC
12 West Capital Management, L.P.
Hudson View Capital LLC
How many institutions hold shares of Maravai LifeSciences Holdings Inc (MRVI)?
As of 2025Q3, 518 institutions hold shares of Maravai LifeSciences Holdings Inc, with a combined market value of approximately 128.65M, accounting for 88.93% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.28%.
What is the biggest source of revenue for Maravai LifeSciences Holdings Inc?
In FY2025Q2, the -- business generated the highest revenue for Maravai LifeSciences Holdings Inc, amounting to -- and accounting for --% of total revenue.
